Oh My Aching Body Understanding Fibromyalgia
|
|
- Benedict Morton
- 6 years ago
- Views:
Transcription
1 Page 1 Oh, My Aching Body: Understanding Fibromyalgia Geneva Clark Briggs, PharmD, BCPS This program has been brought to you by PharmCon Oh, My Aching Body: Understanding Fibromyalgia Accreditation: Pharmacists: L01-P Pharmacy Technicians: L01-T Nurses: N-638 CE Credits: 1.0 contact hour Target Audience: Pharmacists, Technicians & Nurses Program Overview: This program reviews the updated diagnostic criteria for fibromyalgia and the current postulated pathophysiology leading to increased pain perception. The evidence for various prescription and nonprescription therapies for treating this difficult disease will be discussed. The program includes information on pharmacologic treatments, patient counseling, and a question and answer period. PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Objectives: Summarize the issues with pain perception in fibromyalgia Review the efficacy of prescription agents for managing fibromyalgia Recommend nonprescription alternatives for managing fibromyalgia in appropriate patients This program has been brought to you by PharmCon Oh, My Aching Body: Understanding Fibromyalgia Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her Doctor of Pharmacy and Bachelor of Science in Pharmacy degrees from Virginia Commonwealth University, Medical College of Virginia. Dr. Briggs is a clinical associate with MedOutcomes, Inc, where she develops and presents educational programs for pharmacists. Speaker Disclosure: Dr. Briggs has no actual or potential conflicts of interest in relation to this program This program has been brought to you by PharmCon PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Outline What is fibromyalgia and how do you know if someone has it? What is thought to cause fibromyalgia related pain? How is it treated? Nonpharmacologic Prescription therapies Alternative medications
2 Page 2 Clinical Features of FM WIDESPREAD PAIN Chronic, widespread pain is the defining feature of FM Patient descriptors of pain include: aching, exhausting, nagging, and hurting TENDERNESS Presence of tender points Most patients also have tenderness to pressure, heat, cold, electrical pain SLEEP DISTURBANCES Characterized by nonrestorative sleep and increased awakenings Abnormalities in the continuity of sleep and sleep architecture Reduced slow-wave sleep Abnormal alpha wave intrusion in non- REM sleep FATIGUE/STIFFNESS Morning stiffness and fatigue are common characteristics of FM Overlap Between Fibromyalgia and Related Syndromes Fibromyalgia 2-6% of population Defined by widespread pain and tenderness Regional Pain Syndromes Irritable Bowel Painful bladder/ interstitial cystitis Tempromandibular Disorder Tension headache Vulvodynia Pain and/or sensory amplification Arthritis Rheum. 1995;38:19-28; Arthritis Rheum. 1990:33: ; Arthritis Rheum. 2001;44: ; Am J Med Sci. 1998;315: Clauw DJ, et al. Neuroimmunomodulation. 1997;4: Chronic Fatigue Syndrome (CFS) 1% of population Fatigue and 4 of 8 minor criteria Psychiatric Disorders Major depression OCD Bipolar PTSD Generalized anxiety disorder Panic attack Somatoform Disorders 4% of population Multiple unexplained symptoms no organic findings Medical Disorder 1 Medical and Psychiatric Comorbidities with FM Prevalence (%) Chronic fatigue syndrome IBS TMD 75 Tension and migraine headache Multiple chemical sensitivities Interstitial cystitis Chronic pelvic pain 18 Psychiatric Disorder 2 OCD=obsessive-compulsive disorder. PTSD=posttraumatic stress disorder. 1. Best Pract Res Clin Rheumatol. 2003;17: J Clin Psychiatry. 2006;67: Lifetime Prevalence (%) Major mood disorder 73.1 Major depressive disorder 62.0 Bipolar disorder 11.1 Anxiety disorder 55.6 Panic disorder 28.7 PTSD 21.3 Social phobia 19.4 OCD 6.5 Interactive Question What percentage of FM patients are women? a % b % c %
3 Page 3 Who Gets Fibromyalgia? 2-6% of population 4-6 times > diagnosis in females All ages but peak Some ethnic groups may have higher risk but conflicting data Fibromyalgia ACR Diagnostic Criteria History of widespread pain ( 3 months) Above and below the waist Bilaterally In the axial skeleton Pain in 11 of 18 specific fibromyalgia tender points on digital palpation Palpation force: 4 kg/1.4 cm 2 Approximately pressure required to blanche the fingernail of the examiner Pain. 2006;124: , Lupus. 1998;7: , Lupus. 2003;12: , Arthritis Rheum. 1995;38:19-28., Ethn Dis. 2008;18: , Pain Med. 2003;4: , J Palliat Med. 2006;9: J Rheumatol. 1997;24: , Arthritis Rheum. 1990;33: Issues with Tender Point Count The threshold of 11/18 tender points may be too insensitive Most clinicians don t use TPC for diagnosis Many don t do it correctly FM diagnostic criteria should reflect better understanding of pathophysiology in FM ACR Preliminary Diagnostic Criteria for Fibromyalgia 1. Pain & symptoms present for 3 months or longer 2. Widespread pain index (WPI, 0-19) 3. Symptom severity scale (SS, 0-12) Fatigue Waking unrefreshed Cognitive symptoms Somatic symptoms Pain 3 mo + WPI > 7 & SS >5 OR WPI 3-6 & SS > 9 Arthritis Care Res. 2010; 62:
4 Page 4 Pathogenesis of FM and Related Conditions Genetics Triggers Mechanisms Relationship between physiological and psychological factors Disordered sensory processing Autonomic/neuroendocrine dysfunction Arch Intern Med. 1999;159(8): Best Pract Res Clin Rheumatol. 2003;17(4): Ann Intern Med. 2007;146(10): Genetic Factors in FM 5-HT2A receptor polymorphism T/T phenotype Serotonin transporter COMT (catecholamine o-methyl transferase) Arthritis Rheum. 2004;50(3): Hum Mol Genet. 2005;14(1): Neurobiol Dis 1999;6:433-9 Arthritis Rheum. 1999;42: Rheumatol Int. 2003;23:104-7 >8 Odds Ratio for First-Degree Relatives to Develop Fibromyalgia Stressors Capable of Triggering FM and Related Illnesses Peripheral pain syndromes Infections (eg,parvovirus, Lyme disease, Q fever, hepatitis) Physical trauma (automobile accidents) Psychological stress/distress Hormonal alterations (eg, hypothyroidism) Certain catastrophic events (war, but not natural disasters) Fibromyalgia Pathophysiology: The Role of Plasticity in Chronic Pain Normal Healing Pain Relief Injury Acute Pain Hyperalgesia Healing With Plasticity Chronic Pain Allodynia Neuroimmunomodulation. 1997;4(3): Med Hypotheses. 2004;63(4): Marcus DM. Am Fam Physician. 2000;61:
5 Pain Intensity Page 5 Central Sensitization in Chronic Pain Enhanced Pain Processing fmri findings Tissue Damage PERIPHERAL ACTIVITY Nerve Damage Hyperalgesia Decreased threshold to peripheral stimuli Spontaneous Pain CENTRAL SENSITIZATION Allodynia Increased Expansion of Spontaneous Receptive field activity Comparison of 16 FM Patients vs 16 Healthy Controls fmri=functional magnetic resonance imaging. Arthritis Rheum. 2002;46(5): Fibromyalgia Subjective pain control Stimulus Intensity, kg/cm 2 Similar pressure produced significantly greater activation at 13 regions in the patient group and 1 region in the control group Stimulus pressure control 4.5 Fibromyalgia Pathophysiology Fibromyalgia Pathophysiology Ascending pathways Descending Modulation Descending modulatory pathways Facilitation Substance P Glutamate and EAAs NGF Inhibition Descending antinociceptive pathways Norepinephrine and serotonin (5-HT 1a,b ) Opioids Mechanism Central sensitization Abnormalities of descending inhibitory pain pathways Neurotransmitter abnormalities Comorbid psychiatric conditions Description Amplification of pain in the spinal cord via spontaneous nerve activity, expanded receptive fields, and augmented stimulus responses Dysfunction in brain centers (or the pathways from these centers) that normally downregulate pain signaling in the spinal cord Decreased serotonin and norepinephrine in the CNS leading to aberrant pain signaling Decreased dopamine transmission in the brain leading to chronic pain via unclear mechanisms Depression, anxiety, PTSD, and somatization, which may predispose individuals to the development of fibromyalgia 5-HT=serotonin. EAA=excitatory amino acid. NGF=nerve growth factor. J Neurosci. 2007;27: ; Prog Neurobiol. 2002;66: ; Arthritis Rheum. 1992;35: ; Arthritis Rheum. 1994;37: ; Pain. 2007;8: CNS, central nervous system; PTSD, post-traumatic stress disorder. Ann Intern Med. 2007;146:
6 Page 6 From Mechanism to Treatment Dually Focused Treatment Primarily a neural disease and central sensitization plays a critical role (neuropathic pain) Deficiency of noradrenergicserotonergic activity and/or excess levels of excitatory neurotransmitters Lack of sleep or exercise increase pain and other somatic symptoms Treatments aimed at the periphery (ie, topicals, injections) are not very efficacious Subgroups of patients with FM need different treatments Drugs to target these neurotransmitters Exercise, sleep hygiene, and other behavioral interventions are effective therapies for biological reasons Symptoms of pain, fatigue, etc Nociceptive processes Neuroendocrine and sleep dysfunction Disordered sensory processing Functional consequences of symptoms Increased distress Decreased activity Isolation Poor sleep Maladaptive illness behaviors Thoughts affect pain levels Cognitive therapies are effective in FM and have a Arch Intern Med. 1999;159: biological substrate Best Pract Res Clin Rheumatol. 2003;17: Ann Intern Med. 2007;146: Best Pract Res Clin Rheumatol. 2003;17: Pharmacologic therapies to improve symptoms Nonpharmacologic therapies to address dysfunction Nonpharmacological Therapies Poll Question Strong Evidence Education Aerobic exercise Cognitive-behavioral therapy (CBT) Modest Evidence Strength training Hypnotherapy Balneotherapy Weak Evidence Chiropractic, manual, and massage therapy Acupuncture, electrotherapy, ultrasound Meditation Biofeedback Yoga No Evidence Tender-point injections (TPIs), flexibility exercise Which is the most important treatment of fibromyalgia? a. Medications b. Exercise c. Psychotherapy d. Patient education JAMA. 2004;292: Clin Exp Rheumatol. 2009;27(5 Suppl 56):S29-32, S46-50.
7 Page 7 Patient Education The Most Important Treatment for FM Validate pain Explain disease Realistic expectations Goal is not to be pain free but to have reduced/manageable pain Patient responsibilities J Rheumatol. 1994;21: Patient Educ Couns. 2002;48: Am J Phys Med Rehabil. 2003;82: Arch Intern Med. 2007;167: Exercise Aerobic exercise is nearly universally beneficial Tolerance & adherence are biggest issues To maximize benefits Begin gradually after pharmacologic therapy Begin with stretching, low-impact exercises; avoid strength training until later Goal is to achieve regular, consistent physical activity Cognitive Behavioral Therapy (CBT) A program designed to teach patients techniques to Reduce their symptoms Increase coping strategies Identify and eliminate maladaptive illness behaviors Shown to be effective for nearly any chronic medical illness Pharmacologic Approaches
8 Page 8 Pharmacologic Management of Neuropathic Pain Pharmacological Therapies in FM Central Sensitization Calcium Channels - Gabapentin, pregabalin, lamotrigine J Pain Symp Management Peripheral Sensitization Sodium Channels - TCAs, carbamazepine, oxcarbamazepine, phenytoin, lamotrigine, lidocaine, mexiletine Strong Evidence No Evidence Dual reuptake inhibitors Opioids Tricyclic compounds Corticosteroids (amitriptyline, cyclobenzaprine) NSAIDs SNRIs (milnacipran, duloxetine) Benzodiazepine and Pregabalin nonbenzodiazepine Modest Evidence hypnotics Tramadol Guaifenesin Gabapentin Venlafaxine SSRIs Gamma-hydroxybutyrate Dopamine agonists SNRI=serotonin norepinephrine reuptake inhibitor. SSRI=selective serotonin reuptake inhibitor. JAMA. 2004;292: , Ann Rheum Dis. 2008;67(4): , J Rheumatol. 2003;30(5): , Curr Opin Rheumatol. 2008;20(3): Arthritis Rheum. 2007;56(4): Pain Medication Usage Patterns in FM Relative Activity on Serotonin and Norepinephrine Reuptake Serotonin Mixed Norepinephrine Citalopram Fluvoxamine Sertraline Paroxetine Venlafaxine Amitriptyline Duloxetine Milnacipran Cyclobenzaprine Imipramine Maprotiline Desipramine Nortriptyline Fluoxetine P<.001. COX=cyclo-oxygenase. NSAID=nonsteroidal anti-inflammatory drug. Int J Clin Pract. 2007;61(9): Antidepressant Pain Med. 2000;1(4): Analgesic Antidepressant Best evidence of efficacy in FM
9 Pain Reduction % of Patients With Pain Relief Page 9 Duloxetine (Cymbalta ) Pain Relief in Patients With FM FDA-approved for FM An SNRI Dosage should be titrated until recommended dose of 60 mg/day is achieved Common side effects: nausea, headache, dry mouth, dizziness, somnolence, constipation, and fatigue Pain. 2008;136(3): Pain. 2005;119(1-3): Duloxetine 60 mg/day Placebo n=260 n=257 Milnacipran (Savella ) Mean Change in Pain Over Time FDA-approved for FM An SNRI, though its norepinephrine reuptake inhibition predominates Dosage needs to be titrated to recommended dose 100 mg/day (50 mg twice daily) Side effects: nausea, constipation, hot flush, hyperhidrosis, vomiting, palpitations, dry mouth, and hypertension Week J Rheumatol. 2005;32:
10 Page 10 Pregabalin (Lyrica ) First FDA-approved medication for FM Binds to the alpha2-delta ( 2 ) site of voltage-gated calcium channels in the CNS Dosage needs to be titrated, until recommended dose of mg/day is achieved Side effects: dizziness, somnolence, headache, dry mouth, constipation, blurred vision, weight gain, and difficulty with concentration/attention Comparing the 3 Approved Agents Meta-analysis of 11 trials (>6,000 pts) All reduce pain ~20-30% Duloxetine & pregabalin > milnacipran in reducing pain and sleep disturbances Duloxetine > milnacipran & pregabalin in reducing depressed mood Milnacipran & pregabalin > duloxetine in reducing fatigue J. Pain 2010:11; Gabapentin (Neurontin ) Indicated for post-herpetic neuralgia Binds to the alpha2-delta ( 2 ) site of voltage-gated calcium channels in the CNS 51% of 75 FM subjects had 30% reduction in pain Titrate dose to 1,200-2,400 mg/day Side effects: dizziness, somnolence, and peripheral edema Arthritis Rheum. 2007;56: Tramadol Dual action Mild opioid action plus mild serotonin and norepinephrine action Modest evidence of efficacy Side effects: nausea, dizziness, somnolence, constipation Reports of Classic opioid withdrawal with sudden discontinuation Abuse and dependency potential Arthritis Rheum. 2005;53: Pain Pract. 2009;9: Ther Clin Risk Manag. 2007;3:
11 Page 11 Pramipexole (Mirapex ) Dopamine receptor agonist Modest evidence of efficacy Placebo-controlled study 82% improved pain 42% had a >50% decrease in pain when taken in addition to other medications Also improved: fatigue and function Dosing: start with mg every night, gradual increase up to 4.5 mg every night 33% prevalence of RLS in FM Arthritis Rheum. 2005;52: J Clin Sleep Med. 2010;6: Poll Question Agents which decrease peripheral sensitization are effective in treating fibromyalgia a. True b. False Agents to Reduce Peripheral Nociceptive Input Medicine Class Topical analgesics Muscle relaxers Capsaicin Trigger point injections Botulinum toxin type A NSAIDs, COX-2 inhibitors Little or No Evidence of Benefit in FM Case Presentation AJ is a 47 year old female with a 4 year history of FM Currently being treated with pregabalin and milnacipran Practices good sleep hygiene and walks 20 mins 3 x/week Prior treatments: CBT, acupuncture, TENS Still having moderate pain and significant fatigue Asks Are there any supplements that might help me?
12 Page 12 Supplements & Alternative Medications for FM 43% in one phone survey took at least one Most common were omega fatty acids, glucosamine, gingko In a FM clinic: 35% used vitamin C, 31% vitamin E, 29% magnesium, 25% vitamin B complex, 24% green tea J Womens Health. 2009;18: , J Altern Complement Med. 2010;16: J Int Med Res. 2002;30: Mayo Clin Proc. 2005;80: Intravenous micronutrient therapy (IVMT, Myer s Cocktail) 1 randomized, placebo controlled trial (n=31) Once a week infusion for 8 weeks Significant placebo effect, greater but not statistically significant effect of IVMT J Altern Complement Med. 2009;15: Alternative Medications Chinese herbal medicine Anthocyanidins S-adenosylmethionine (SAMe) 400 mg bid diarrhea, dyspepsia, anxiety, headache, mania, insomnia, allergy, and rashes serotonin J Altern Complement Med. 2010;16: J Nutr Environ Med 2000;10: Scand J Rheumatol 1991;20: Alternative Medicines Homeopathy Rhus toxicodendron (6c potency) tid Arnica montana, Bryonia alba and R. toxicodendron (all of 6c potency) Adverse effects: allergic reactions, photodermatitis Clin Rheumatol. 2010;29: Br Med J 1989;299: Br Homeopath J 1986;75: Rheumatology 2004;43:
13 Page 13 Case 47 year on pregabalin and milnacipran Would an alternative medicine be beneficial? Which one would you suggest to her? Overall Management of FM Educate the patient Multidisciplinary and combination therapy approach Pharmacologic and nonpharmacologic therapies Target medications to underlying pathophysiology Individualized treatment goals Successful outcome does not mean painfree Notes Notes
Fibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationHeadaches, 37, 42 Hypnotherapy, 101t, 106 Hypothalamic-pituitary-adrenal (HPA) axis, 59, 61, 63, 64, 65
INDEX Note: page numbers in italic typeface indicate figures. Page numbers followed by a t indicate tables. Abbreviations are for terms listed on pages 135-137. Acetaminophen/tramadol in fibromyalgia,
More informationFibromyalgia: What Primary Care Providers Need to Know
Learning Objectives Fibromyalgia: What Primary Care Providers Need to Know Susan Hutchinson, MD Director, Orange County Migraine & Headache Center Volunteer Clinical Faculty, UC Irvine Department of Family
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More information10/19/12. Moving from Mechanisms to Treatment in Chronic Pain Patients. Daniel Clauw, MD Disclosures
10/19/12 Moving from Mechanisms to Treatment in Chronic Pain Patients Daniel Clauw, MD University of Michigan Ann Arbor, MI Daniel Clauw, MD Disclosures Research/Grants: Forest Laboratories, Inc.; Nuvo
More informationFIBROMYALGIA. Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017
FIBROMYALGIA Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017 Sir William Osler When a patient with arthritis comes in the front door, I try to go out the back door. FEINBERG S COROLLARY
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abuse, child, 255 Activities of daily living, energy conservation in, 385 Acupuncture, 400 401 Adrenergic receptors, in pain generation, 286
More informationFran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia
Fran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia Case Presentation-Fibromyalgia 30 year old female Chief complaint of back
More informationEvolving Treatments for Patients with Fibromyalgia
4:30pm - 5:30pm: Breakout 5 - Women s Health Option C: Evolving Treatments for Patients with Fibromyalgia ACPE UAN 0107-0000-10-027-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives
More informationFIBROMYALGIA. Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University
FIBROMYALGIA Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University disclosures I have no conflicts of interest objectives Be able to accurately
More informationMaking sense of fibromyalgia syndrome. Charles Radis D.O. Clinical Professor of Medicine UNECOM
Making sense of fibromyalgia syndrome Charles Radis D.O. Clinical Professor of Medicine UNECOM Goals 1. How do we diagnose fibromyalgia syndrome in patients presenting with widespread pain? 2. Discuss
More informationObjectives. Objectives. Fibromyalgia overview 2/13/2013. Disclosure. FM research has flourished since 1980s. Acceptance fibromyalgia as a diagnosis
Fibromyalgia overview Robert Bennett M.D. Professor of Medicine Mdii and Nursing OHSU Disclosure Research support : Forest, Jazz, Pfizer Advisory Boards: Lilly, Jazz Speaker Bureaus: None Objectives Objectives
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationMANAGEMENT OF VISCERAL PAIN
MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal
More informationFibromyalgia Update. Presenter: Manfred Harth MD FRCPC
Fibromyalgia Update Presenter: Manfred Harth MD FRCPC Fibromyalgia Update Manfred Harth MD FRCPC Disclosures Member Pfizer Canada Medical Advisory Committee on Lyrica (till April 2013) Abbvie : Payment
More informationCare Management Care Review Collaborative. February 16, 2018 Guest Specialist Dave Williams PHD
Care Management Care Review Collaborative February 16, 2018 Guest Specialist Dave Williams PHD SCR Guidance The case study review is to serve as a learning platform only Input on the cases reviewed are
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationAssistant Professor. Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine.
Assistant Professor Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine. Fibromyalgia Fibromyalgia is a syndrome of chronic pain and the presence of hyperalgesic points at specific anatomical
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationFIBROMYALGIA INGRAM F ANDERSON. Consultant Rheumatologist
FIBROMYALGIA INGRAM F ANDERSON Consultant Rheumatologist Fibromyalgia is a riddle wrapped in a mystery inside an enigma Fibromyalgia not a new Disease. 1904: Gowers coined the term fibrositis to describe
More informationFibromyalgia: What a Pain!
Fibromyalgia: What a Pain! WWW.RN.ORG Reviewed May, 2017, Expires May, 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017 RN.ORG, S.A., RN.ORG, LLC
More informationFibromyalgia. November 3, 2018 Raymond Hong, MD, MBA
Fibromyalgia November 3, 2018 Raymond Hong, MD, MBA The following report is proprietary information and constitutes trade secrets of The MetroHealth System and may not be disclosed in whole or part to
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Fibromyalgia Update Wayne Blount, MD Speaker has no disclosures
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationBEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN
BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN Ronald Januchowski, D.O. 2017 Objectives By the end of the presentation, the learner should be able to: Summarize the risks of opiates when used for non-cancer
More informationTreating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head...
Treating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head... Daniel J. Clauw M.D. dclauw@umich.edu Professor of Anesthesiology, Medicine (Rheumatology), and Psychiatry Director,
More informationFibromyalgia in Family Medicine: Challenges in Pain Management
Fibromyalgia in Family Medicine: Challenges in Pain Management Evidence-based Recommendations The practice recommendations in this presentation are from: The European League Against Rheumatism (EULAR)
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationA Patient s Guide to Fibromyalgia
A Patient s Guide to Fibromyalgia 651 Old Country Road Plainview, NY 11803 Phone: 5166818822 Fax: 5166813332 p.lettieri@aol.com DISCLAIMER: The information in this booklet is compiled from a variety of
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationFibromyalgia. Disclosures. Question 1. Fibromyalgia - Sheetal Desai, MD, MSEd. None
Western Occupational and Environmental Medical Association CME Webinar - August 18, 2011 Fibromyalgia Sheetal Desai, MD MSEd Division of Rheumatology, UC Irvine PLEASE STAND BY - WEBINAR WILL BEGIN AT
More informationManaging the Chronic Pain Patient. (and some stuff about opioids)
Managing the Chronic Pain Patient. (and some stuff about opioids) C. Patrick Carroll, M.D. Assistant Professor Johns Hopkins University School of Medicine Department of Psychiatry and Behavioral Sciences
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationIs There a Chronic Pain Prone Phenotype?
Is There a Chronic Pain Prone Phenotype? Yes, But its Often Much More Than Pain Daniel J. Clauw M.D. Professor of Anesthesiology and Medicine (Rheumatology) Director, Chronic Pain and Fatigue Research
More informationof successful management symptoms can be reduced significantly in a population of FMS sufferers.
Fibromyalgia syndrome is defined as a chronic pain disorder of unknown etiology, characterized by widespread musculoskeletal pain and tender points, alterations in sleep patterns, and changes in neuroendocrine
More informationAddressing Fibromyalgia: From Timely Diagnosis to Individualizing Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMonte H. Moore, MD. Idaho Physical Medicine and Rehabilitation. Meridian, ID
Monte H. Moore, MD Idaho Physical Medicine and Rehabilitation Meridian, ID Chronic pain brief review Opiates important things to know Factors in determining whether to use an opiate What to watch for if
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationFibromyalgia. Resident School December 2013 Mary Lemon
Fibromyalgia Resident School December 2013 Mary Lemon The Basics Condition that causes people to feel pain in the muscles all over their body No one knows what causes it; appears to be a combo of genetic
More informationSpine University s Guide to Fibromyalgia
Spine University s Guide to Fibromyalgia 2 Introduction The official name for fibromyalgia is fibromyalgia syndrome. Fibro means fiber and myalgia means muscular pain or tenderness. Fibromyalgia has been
More informationThe Role of Pregabalin in Fibromyalgia
The Role of Pregabalin in Fibromyalgia Sofia Exarchou Resident at Internal Medicine and Rheumatology at the University Hospital of Skåne, Malmö-Lund Metsovo Greece 2011 History Gowers 1904 Hench 1976 Smythe
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acetaminophen in chronic pain management, 225 Acupuncture in chronic pain management, 251, 338 339 Ajurvedic medicine in chronic pain management,
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationFibromyalgia summary. Patient leaflets from the BMJ Group. What is fibromyalgia? What are the symptoms?
Patient leaflets from the BMJ Group Fibromyalgia summary We all get aches and pains from time to time. But if you have long-term widespread pain across your whole body, you may have a condition called
More informationDr. Melissa Kagarise, PA C
Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More information8/6/18. Definitions. Disclosures. Technician Objectives. Pharmacist Objectives. Chronic Pain. Non-Opioid Alternatives for Chronic Pain Management
Disclosures Non-Opioid Alternatives for Chronic Management Nicholas Cox, PharmD, BCACP Clinical Pharmacist, Intensive Outpatient Clinic, University of Utah Health Pharmacist, Population Health, University
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationNociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation
Learning Objectives Effective, Safe Analgesia An Approach to Appropriate Outpatient Chronic Pain Treatment By the end of this presentation, participants will be able to: Identify multiple factors that
More informationFibro Fog and Fatigue
Fibro Fog and Fatigue Farhan Tahir MD, FACR, ABIHM Board certified in Rheumatology & Integrative and Holistic Medicine Focus of Practice Lets help you Rise and Shine Founder of Pennsylvania s only Integrative
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationDiscussion Questions WHAT ARE SOME POSSIBLE CAUSES OF HER PAIN? WHAT ELSE WOULD YOU LIKE TO KNOW
CLINICAL CASES Case: Ms. FM Case: Ms. FM Ms. FM is a 37-year-old school teacher Under your care for 10 years Unremarkable past history Was in minor car accident 4 months ago Has had progressive generalized
More informationUnderstanding Fibromyalgia
Page 1 Accreditation: Pharmacist 798-000-08-074-L01-P Technicians- 798-000-08-074-L01-T Target Audience: Pharmacists & Technicians CE Credits: 1.0 Credit hour or 0.1 CEU for pharmacists/technicians Expiration
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying,
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationIs Sodium Oxybate a Safe and Effective Treatment for Patients with Fibromyalgia
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Sodium Oxybate a Safe and Effective
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationUnderstanding pain and mental illness Impact on management principles
Understanding pain and mental illness Impact on management principles Chris Alderman Consultant Psychopharmacologist Pain and mental illness - context PAIN MENTAL ILLNESS OTHER FACTORS (personality, history.
More informationOn March 21, 2009, The American Journal of Managed Care
n report n Contemporary Management Strategies for Fibromyalgia On March 21, 2009, The American Journal of Managed Care (AJMC) held a roundtable of clinical, patient advocacy, and managed care experts to
More informationPalliative Care: Treatment at the End of Life
Page 1 Palliative Care: Treatment at the End of Life This webcast has been supported by an educational grant from Purdue Pharma L.P. Mary Lynn McPherson, Pharm.D., BCPS, CDE Professor, University of Maryland
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with
More informationFIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME
FIBROMIALGIA: CLASSIFICAZIONE ED EPIDEMIOLOGIA DELLA SINDROME D.A. Filippini S.C. Reumatologia ASST Grande Ospedale Metropolitano Niguarda Milano MALATTIA DOLORE E RETE TERRITORIALE OSPEDALE NIGUARDA MILANO
More informationHow to Manage Anxiety
How to Manage Anxiety Dr Tony Fernando Psychological Medicine University of Auckland Auckland District Health Board www.insomniaspecialist.co.nz www.calm.auckland.ac.nz Topics How to diagnose How to manage
More informationUnderstanding and Treating Post- Herpetic Neuralgia (PHN)
Understanding and Treating Post- Herpetic Neuralgia (PHN) Mary Lynn McPherson, Pharm.D., BCPS Professor University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu This program has been supported
More informationFIBROMYALGIA ANNE WINKLER MD PHD MO ACP MEETING SEPT 2016
FIBROMYALGIA ANNE WINKLER MD PHD MO ACP MEETING SEPT 2016 DEFINITION CHRONIC MUSCILOSKELETAL DISORDER CHARACTERIZED BY GENERALIZED PAIN AND TENDERNESS AT SPECIFIC ANATOMIC SITES. CRITERIA DEFINED IN 1990
More informationRefractory Central Neurogenic Pain in Spinal Cord Injury. Case Presentation
Refractory Central Neurogenic Pain in Spinal Cord Injury Case Presentation Edwin B. George, MD, PhD Wayne State University John D. Dingell VAMC 2012 Disclosures This continuing education activity is managed
More informationStrategies in Migraine Care
Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives
More informationFunctional Somatic Syndromes Chris Stewart-Patterson, MD
Functional Somatic Syndromes Chris Stewart-Patterson, MD No disclosures CME Program Director Harvard Medical School Occupational Medicine Practice Lancet Functional Somatic Syndromes FSS are characterised
More information3/3/2015 CHRONIC PAIN MARGARET ZOELLERS, MSN, APRN
CHRONIC PAIN MARGARET ZOELLERS, MSN, APRN 1 Pain that persists or recurs > 3-6 months Pain that persists >1 month after injury/event Commonly seems out of proportion to the physical process Cause may be
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationFibromyalgia syndrome (FMS) is characterized
TARGETING NEUROTRANSMITTERS: MODULATING PAIN RESPONSE* Jacquelyn Bainbridge, PharmD, FCCP ABSTRACT Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and is often accompanied
More informationFibromyalgia , The Patient Education Institute, Inc. id Last reviewed: 03/12/2017 1
Fibromyalgia Introduction Fibromyalgia is a common condition that causes pain and fatigue in the muscles, joints, ligaments and tendons. Fibromyalgia affects about 3 to 6% of people worldwide. Fibromyalgia
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationMoving On : Non-Opioid Alternatives for Chronic Pain Management
Winter Meeting February 10, 2018 Moving On : Non-Opioid Alternatives for Chronic Pain Management Nicholas Cox, PharmD, BCACP Clinical Pharmacist, Intensive Outpatient Clinic, University of Utah Health
More informationNew service available for VoY Ryedale practice patients
New service available for VoY Ryedale practice patients Scarborough Pain (Enablement) Service For some time, NHS Scarborough & Ryedale CCG and York Teaching Hospital Foundation Trust have had a service
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationDisclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws
Disclosures Management of Chronic, Non- Terminal Pain No financial disclosures or conflicts of interest to report Michael A. Smith, PharmD, BCPS Clinical Assistant Professor, University of Michigan College
More informationUCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14. Cynthia Kim and Stephen Wilson
UCSF Pediatric Hospital Medicine Boot Camp Pain Session 6/21/14 Cynthia Kim and Stephen Wilson Rules Buzz first and player answers If answer correct, then the player asks teammates if they want to keep
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationFoundations of Pain Management BioPsychoSocial Issues
Foundations of Pain Management BioPsychoSocial Issues MiCCSI David A. Williams, Ph.D. President, American Pain Society Professor of Anesthesiology, Medicine, Psychiatry and Psychology Associate Director,
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More information9/2/2010. Welcome. Nationwide Children s Hospital. Follow the Journey of Children with Chronic Pain. ASPMN Conference September 25, 2010
Follow the Journey of Children with Chronic Pain Sharon Wrona RN-BC, MS, PNP ASPMN Conference September 25, 2010 Welcome Nationwide Children s Hospital 1 Chronic Pain in Children Chronic pain affects approximately
More informationOptimizing Non-Opioid Therapy for Chronic Pain
Optimizing Non-Opioid Therapy for Chronic Pain Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More information